^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Mantle Cell Lymphoma |
| Regimen: | (bortezomib + doxorubicin hydrochloride + Rituxan (rituximab) + prednisolone + cyclophosphamide) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
01/20/2021
Excerpt:
Mantle Cell Lymphoma: INDUCTION THERAPY…Preferred…VR-CAP (bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone)
